{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T23:07:44Z","timestamp":1761606464428,"version":"build-2065373602"},"reference-count":61,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,10,9]],"date-time":"2023-10-09T00:00:00Z","timestamp":1696809600000},"content-version":"am","delay-in-days":738,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Chromatography B"],"published-print":{"date-parts":[[2021,10]]},"DOI":"10.1016\/j.jchromb.2021.122943","type":"journal-article","created":{"date-parts":[[2021,9,30]],"date-time":"2021-09-30T15:12:38Z","timestamp":1633014758000},"page":"122943","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Interspecies comparison of plasma metabolism and sample stabilization for quantitative bioanalyses: Application to (R)-CE3F4 in preclinical development, including metabolite identification by high-resolution mass spectrometry"],"prefix":"10.1016","volume":"1183","author":[{"given":"Balthazar","family":"Toussaint","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Herv\u00e9","family":"Hillaireau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emmanuel","family":"Jaccoulet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Catherine","family":"Cailleau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pauline","family":"Legrand","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yves","family":"Ambroise","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elias","family":"Fattal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.jchromb.2021.122943_b0005","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1038\/nrcardio.2016.25","article-title":"Epidemiology and aetiology of heart failure","volume":"13","author":"Ziaeian","year":"2016","journal-title":"Nat. Rev. Cardiol."},{"issue":"2","key":"10.1016\/j.jchromb.2021.122943_b0010","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1253\/circj.CJ-18-0743","article-title":"Usefulness of Exchanged Protein Directly Activated by cAMP (Epac)1-Inhibiting Therapy for Prevention of Atrial and Ventricular Arrhythmias in Mice","volume":"83","author":"Prajapati","year":"2019","journal-title":"Circ. J."},{"issue":"53","key":"10.1016\/j.jchromb.2021.122943_b0015","doi-asserted-by":"crossref","first-page":"44192","DOI":"10.1074\/jbc.M112.422956","article-title":"Identification of a tetrahydroquinoline analog as a pharmacological inhibitor of the cAMP-binding protein Epac","volume":"287","author":"Courilleau","year":"2012","journal-title":"J. Biol. Chem."},{"issue":"3","key":"10.1016\/j.jchromb.2021.122943_b0020","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/j.bbrc.2013.09.107","article-title":"The (R)-enantiomer of CE3F4 is a preferential inhibitor of human exchange protein directly activated by cyclic AMP isoform 1 (Epac1)","volume":"440","author":"Courilleau","year":"2013","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"4","key":"10.1016\/j.jchromb.2021.122943_b0025","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1007\/s00424-009-0747-y","article-title":"Role of the cAMP-binding protein Epac in cardiovascular physiology and pathophysiology","volume":"459","author":"M\u00e9trich","year":"2010","journal-title":"Pflugers Arch."},{"issue":"2","key":"10.1016\/j.jchromb.2021.122943_b0030","first-page":"253","article-title":"Epac activation, altered calcium homeostasis and ventricular arrhythmogenesis in the murine heart, Pflugers Arch - Eur","volume":"457","author":"Hothi","year":"2008","journal-title":"J. Physiol."},{"key":"10.1016\/j.jchromb.2021.122943_b0035","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1093\/cvr\/cvu242","article-title":"Exchange protein directly activated by cAMP 1 promotes autophagy during cardiomyocyte hypertrophy","volume":"105","author":"Laurent","year":"2015","journal-title":"Cardiovasc. Res."},{"key":"10.1016\/j.jchromb.2021.122943_b0040","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1042\/BST20140033","article-title":"Epac proteins: specific ligands and role in cardiac remodelling","volume":"42","author":"Bisserier","year":"2014","journal-title":"Biochem. Soc. Trans."},{"key":"10.1016\/j.jchromb.2021.122943_b0045","first-page":"2200","article-title":"Exchange-protein activated by cAMP (EPAC) regulates L-type calcium channel in atrial fibrillation of heart failure model","volume":"23","author":"Zhang","year":"2019","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"key":"10.1016\/j.jchromb.2021.122943_b0050","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1097\/MPA.0b013e318160748f","article-title":"The cAMP\/Epac1\/Rap1 Pathway in Pancreatic Carcinoma","volume":"37","author":"Lorenz","year":"2008","journal-title":"Pancreas"},{"issue":"1-2","key":"10.1016\/j.jchromb.2021.122943_b0055","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1007\/s11010-017-2959-3","article-title":"Role of exchange protein directly activated by cAMP (EPAC1) in breast cancer cell migration and apoptosis","volume":"430","author":"Kumar","year":"2017","journal-title":"Mol. Cell. Biochem."},{"key":"10.1016\/j.jchromb.2021.122943_b0060","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.3892\/or.2017.5442","article-title":"EPAC1 overexpression is a prognostic marker and its inhibition shows promising therapeutic potential for gastric cancer","volume":"37","author":"Sun","year":"2017","journal-title":"Oncol. Rep."},{"key":"10.1016\/j.jchromb.2021.122943_b0065","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1042\/BST0331330","article-title":"Cyclic nucleotide signalling: a molecular approach to drug discovery for Alzheimer\u2019s disease","volume":"33","author":"McPhee","year":"2005","journal-title":"Biochem. Soc. Trans."},{"key":"10.1016\/j.jchromb.2021.122943_b0070","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1002\/ajmg.b.30976","article-title":"An association between Epac-1 gene variants and anxiety and depression in two independent samples","volume":"153B","author":"Middeldorp","year":"2010","journal-title":"Am. J. Med. Genet."},{"key":"10.1016\/j.jchromb.2021.122943_b0075","unstructured":"M4S Common Technical Document for the Registration of Pharmaceuticals for Human Use - Safety, Committee for Human Medicinal Products (2003) 113."},{"key":"10.1016\/j.jchromb.2021.122943_b0080","unstructured":"M4E(R2) - Common technical document for the registration of pharmaceuticals for human use - Efficacy, Committee for Human Medicinal Products. (2016) 53."},{"key":"10.1016\/j.jchromb.2021.122943_b0085","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2014.00174","article-title":"Implementation of pharmacokinetic and pharmacodynamic strategies in early research phases of drug discovery and development at Novartis Institute of Biomedical Research","volume":"5","author":"Tuntland","year":"2014","journal-title":"Front. Pharmacol."},{"issue":"9","key":"10.1016\/j.jchromb.2021.122943_b0090","doi-asserted-by":"crossref","first-page":"2401","DOI":"10.1016\/0006-2952(71)90240-1","article-title":"Deformylation of 4,4\u2019-diformamidodiphenyl sulfone (DFD) by mammalian liver homogenates","volume":"20","author":"Chiou","year":"1971","journal-title":"Biochem. Pharmacol."},{"issue":"9","key":"10.1016\/j.jchromb.2021.122943_b0095","doi-asserted-by":"crossref","first-page":"2409","DOI":"10.1016\/0006-2952(71)90241-3","article-title":"Deformylation of 4,4\u2019-diformamidodiphenyl sulfone (DFD) by plasma of certain mammals","volume":"20","author":"Gleason","year":"1971","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.jchromb.2021.122943_b0100","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/S0090-9556(24)15279-8","article-title":"In vitro metabolism of a new anticancer agent, 6-N-formylamino-12,13-dihydro-1,11-dihydroxy-13-(\u03b2-D-glucopyranosil)5H-indolo [2,3-A]pyrrolo [3,4-C]carbazole-5,7(6H)-dione (NB-506), in mice, rats, dogs, and humans","volume":"27","author":"Takenaga","year":"1998","journal-title":"Drug Metabol. Disposit."},{"key":"10.1016\/j.jchromb.2021.122943_b0105","doi-asserted-by":"crossref","unstructured":"L. Di, The Impact of Carboxylesterases in Drug Metabolism and Pharmacokinetics, Curr Drug. Metab. 20 (2019) 91\u2013102. 10.1389200219666180821094502.","DOI":"10.2174\/1389200219666180821094502"},{"key":"10.1016\/j.jchromb.2021.122943_b0110","doi-asserted-by":"crossref","first-page":"412","DOI":"10.3390\/molecules13020412","article-title":"Structure and Catalytic Properties of Carboxylesterase Isozymes Involved in Metabolic Activation of Prodrugs","volume":"13","author":"Hosokawa","year":"2008","journal-title":"Molecules"},{"key":"10.1016\/j.jchromb.2021.122943_b0115","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1016\/j.bcp.2005.09.002","article-title":"Butyrylcholinesterase, paraoxonase, and albumin esterase, but not carboxylesterase, are present in human plasma","volume":"70","author":"Li","year":"2005","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.jchromb.2021.122943_b0120","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.4155\/bio-2019-0238","article-title":"Sample stabilization strategies: a case study review of unique sample collection and handling procedures","volume":"11","author":"Ohnmacht","year":"2019","journal-title":"Bioanalysis"},{"key":"10.1016\/j.jchromb.2021.122943_b0125","doi-asserted-by":"crossref","first-page":"3197","DOI":"10.1128\/AAC.00500-06","article-title":"Rapid Degradation of Oseltamivir Phosphate in Clinical Samples by Plasma Esterases","volume":"50","author":"Lindegardh","year":"2006","journal-title":"Antimicrob Agents Chemother."},{"issue":"5","key":"10.1016\/j.jchromb.2021.122943_b0130","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1002\/bmc.2838","article-title":"Stabilization of zeylenone in rat plasma by the presence of esterase inhibitors and its LC-MS\/MS assay for pharmacokinetic study","volume":"27","author":"Wei","year":"2013","journal-title":"Biomed. Chromatogr."},{"key":"10.1016\/j.jchromb.2021.122943_b0135","first-page":"75","article-title":"Development and validation of a dried blood spot LC-MS\/MS assay to quantify gemcitabine in human whole blood: a comparision with and without cytidine deaminase inhibitor","author":"Dp","year":"2015","journal-title":"Int. J. Pharm. Pharm. Sci."},{"issue":"2","key":"10.1016\/j.jchromb.2021.122943_b0140","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/0006-2952(66)90064-5","article-title":"Evidence for pilocarpine transformation by serum","volume":"15","author":"Lavallee","year":"1966","journal-title":"Biochem. Pharmacol."},{"issue":"2","key":"10.1016\/j.jchromb.2021.122943_b0145","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1038\/aps.2017.90","article-title":"Conversion and pharmacokinetics profiles of a novel pro-drug of 3- n -butylphthalide, potassium 2-(1-hydroxypentyl)-benzoate, in rats and dogs","volume":"39","author":"Li","year":"2018","journal-title":"Acta Pharmacol. Sin."},{"issue":"8","key":"10.1016\/j.jchromb.2021.122943_b0150","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1016\/0006-2952(94)90200-3","article-title":"Differences in the kinetic properties, effect of calcium and sensitivity to inhibitors of paraoxon hydrolase activity in rat plasma and microsomal fraction from rat liver","volume":"48","author":"Gil","year":"1994","journal-title":"Biochem. Pharmacol."},{"issue":"2","key":"10.1016\/j.jchromb.2021.122943_b0155","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/S1570-0232(03)00574-9","article-title":"Determination of irinotecan (CPT-11) and SN-38 in human whole blood and red blood cells by liquid chromatography with fluorescence detection","volume":"795","author":"de Jong","year":"2003","journal-title":"J. Chromatogr. B"},{"issue":"10","key":"10.1016\/j.jchromb.2021.122943_b0160","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1002\/bmc.1404","article-title":"An HPLC Assay for the Lipophilic Camptothecin Analog AR-67 Carboxylate and Lactone in Human Whole Blood","volume":"24","author":"Tsakalozou","year":"2010","journal-title":"Biomed. Chromatogr."},{"key":"10.1016\/j.jchromb.2021.122943_b0165","doi-asserted-by":"crossref","DOI":"10.1002\/bmc.4771","article-title":"Validation of an analytical method using HPLC\u2013MS\/MS to quantify osimertinib in human plasma and supplementary stability results","volume":"34","author":"van Veelen","year":"2020","journal-title":"Biomed. Chromatogr."},{"key":"10.1016\/j.jchromb.2021.122943_b0170","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpba.2019.112955","article-title":"Development and validation of a UPLC\u2013MS\/MS method for simultaneous determination of vicagrel and its major metabolites in rat or human plasma: An optimized novel strategy for the stabilization of vicagrel","volume":"179","author":"Tai","year":"2020","journal-title":"J. Pharm. Biomed. Anal."},{"issue":"1-2","key":"10.1016\/j.jchromb.2021.122943_b0175","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.ijpharm.2005.03.022","article-title":"Development and application of high throughput plasma stability assay for drug discovery","volume":"297","author":"Di","year":"2005","journal-title":"Int. J. Pharm."},{"issue":"1","key":"10.1016\/j.jchromb.2021.122943_b0180","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1038\/sj.clpt.6100235","article-title":"Model-based Drug Development","volume":"82","author":"Lalonde","year":"2007","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.jchromb.2021.122943_b0185","doi-asserted-by":"crossref","first-page":"FSO306","DOI":"10.4155\/fsoa-2017-0152","article-title":"Quantitative translational modeling to facilitate preclinical to clinical efficacy & toxicity translation in oncology","volume":"4","author":"Zhu","year":"2018","journal-title":"Future Sci. OA"},{"issue":"8","key":"10.1016\/j.jchromb.2021.122943_b0190","doi-asserted-by":"crossref","first-page":"4626","DOI":"10.1039\/C8RA08594C","article-title":"Interspecies differences in stability kinetics and plasma esterases involved in hydrolytic activation of curcumin diethyl disuccinate, a prodrug of curcumin","volume":"9","author":"Ratnatilaka Na Bhuket","year":"2019","journal-title":"RSC Adv."},{"key":"10.1016\/j.jchromb.2021.122943_b0195","doi-asserted-by":"crossref","first-page":"70","DOI":"10.2174\/187231209788654081","article-title":"Esterase Activities in the Blood, Liver and Intestine of Several Preclinical Species and Humans","volume":"3","author":"Berry","year":"2009","journal-title":"Drug Metabol. Lett."},{"key":"10.1016\/j.jchromb.2021.122943_b0200","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1002\/jhet.5570290436","article-title":"Synthesis of 7- and 5,7-substituted-6-fluoro-2-methyl-1,2,3,4-tetrahydroquinolines: Convenient precursors of quinolone antibacterial agents","volume":"29","author":"Bouyssou","year":"1992","journal-title":"J. Heterocycl. Chem."},{"key":"10.1016\/j.jchromb.2021.122943_b0205","unstructured":"Guideline on Bioanalytical Method Validation, European Medicines Agency. (2011). https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/guideline-bioanalytical-method-validation_en.pdf."},{"key":"10.1016\/j.jchromb.2021.122943_b0210","first-page":"579","article-title":"Harmonization of strategies for the validation of quantitative analytical procedures. A SFSTP proposal\u2014part I","volume":"36","author":"Hubert","year":"2004","journal-title":"J. Pharm. Biomed. Anal."},{"issue":"1","key":"10.1016\/j.jchromb.2021.122943_b0215","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.jpba.2007.06.013","article-title":"Harmonization of strategies for the validation of quantitative analytical procedures. A SFSTP proposal\u2014part II","volume":"45","author":"Hubert","year":"2007","journal-title":"J. Pharm. Biomed. Anal."},{"issue":"1","key":"10.1016\/j.jchromb.2021.122943_b0220","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.jpba.2007.06.032","article-title":"Harmonization of strategies for the validation of quantitative analytical procedures. A SFSTP proposal\u2014part III","volume":"45","author":"Hubert","year":"2007","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.jchromb.2021.122943_b0225","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.jchromb.2017.01.036","article-title":"An ultra performance liquid chromatography-tandem mass spectrometry method for the therapeutic drug monitoring of isavuconazole and seven other antifungal compounds in plasma samples","volume":"1046","author":"Toussaint","year":"2017","journal-title":"J. Chromatogr. B"},{"key":"10.1016\/j.jchromb.2021.122943_b0230","doi-asserted-by":"crossref","first-page":"001","DOI":"10.24947\/2380-5552\/1\/1\/00101","article-title":"Cabozantinib Loaded DSPE-PEG2000 Micelles as Delivery System: Formulation, Characterization and Cytotoxicity Evaluation","volume":"1","author":"Yang","year":"2015","journal-title":"BAOJ Pharm. Sci."},{"key":"10.1016\/j.jchromb.2021.122943_b0235","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1023\/A:1016121319668","article-title":"A novel phase inversion-based process for the preparation of lipid nanocarriers","volume":"19","author":"Heurtault","year":"2002","journal-title":"Pharm. Res."},{"issue":"1","key":"10.1016\/j.jchromb.2021.122943_b0240","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1002\/jat.727","article-title":"A good practice guide to the administration of substances and removal of blood, including routes and volumes","volume":"21","author":"Diehl","year":"2001","journal-title":"J. Appl. Toxicol."},{"key":"10.1016\/j.jchromb.2021.122943_b0245","series-title":"The Laboratory Mouse","first-page":"331","article-title":"Haematology of the Mouse","author":"Bolliger","year":"2012"},{"issue":"10","key":"10.1016\/j.jchromb.2021.122943_b0250","doi-asserted-by":"crossref","first-page":"3979","DOI":"10.1002\/jps.23258","article-title":"Species Difference of Esterase Expression and Hydrolase Activity in Plasma","volume":"101","author":"Bahar","year":"2012","journal-title":"J. Pharm. Sci."},{"issue":"17","key":"10.1016\/j.jchromb.2021.122943_b0255","doi-asserted-by":"crossref","first-page":"6383","DOI":"10.1021\/bi047326v","article-title":"Structural and Catalytic Diversity within the Amidohydrolase Superfamily","volume":"44","author":"Seibert","year":"2005","journal-title":"Biochemistry"},{"issue":"2","key":"10.1016\/j.jchromb.2021.122943_b0260","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1006\/bbrc.1997.7872","article-title":"Human Serum Paraoxonase Is Inhibited in EDTA Plasma","volume":"242","author":"Mackness","year":"1998","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.jchromb.2021.122943_b0265","doi-asserted-by":"crossref","unstructured":"A. Tvarijonaviciute, F. Tecles, M. Caldin, S. Tasca, J. Cer\u00f3n, Validation of spectrophotometric assays for serum paraoxonase type-1 measurement in dogs, 73 (2012) 8.","DOI":"10.2460\/ajvr.73.1.34"},{"issue":"10","key":"10.1016\/j.jchromb.2021.122943_b0270","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1016\/0006-2952(95)00071-7","article-title":"Species differences in hydrolysis of isocarbacyclin methyl ester (TEI-9090) by blood esterases","volume":"49","author":"Minagawa","year":"1995","journal-title":"Biochem. Pharmacol."},{"issue":"2","key":"10.1016\/j.jchromb.2021.122943_b0275","doi-asserted-by":"crossref","first-page":"147","DOI":"10.2133\/dmpk.21.147","article-title":"Involvement of Human Blood Arylesterases and Liver Microsomal Carboxylesterases in Nafamostat Hydrolysis","volume":"21","author":"Yamaori","year":"2006","journal-title":"Drug Metab. Pharmacokinet."},{"issue":"22","key":"10.1016\/j.jchromb.2021.122943_b0280","doi-asserted-by":"crossref","first-page":"4983","DOI":"10.1021\/bi00693a030","article-title":"Hydrolysis of phosphonate esters catalyzed by 5\u2019-nucleotide phosphodiesterase","volume":"14","author":"Kelly","year":"1975","journal-title":"Biochemistry"},{"issue":"8","key":"10.1016\/j.jchromb.2021.122943_b0285","doi-asserted-by":"crossref","first-page":"2906","DOI":"10.1021\/jm049011j","article-title":"Identification and Characterization of Novel Benzil (Diphenylethane-1,2-dione) Analogues as Inhibitors of Mammalian Carboxylesterases","volume":"48","author":"Wadkins","year":"2005","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.jchromb.2021.122943_b0290","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1093\/toxsci\/58.1.118","article-title":"Interactions of the Organophosphates Paraoxon and Methyl Paraoxon with Mouse Brain Acetylcholinesterase","volume":"58","author":"Kardos","year":"2000","journal-title":"Toxicol. Sci."},{"key":"10.1016\/j.jchromb.2021.122943_b0295","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1093\/toxsci\/kfh163","article-title":"Comparison of Chlorpyrifos-Oxon and Paraoxon Acetylcholinesterase Inhibition Dynamics: Potential Role of a Peripheral Binding Site","volume":"80","author":"Kousba","year":"2004","journal-title":"Toxicol. Sci."},{"key":"10.1016\/j.jchromb.2021.122943_b0300","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1093\/toxsci\/kfj094","article-title":"Concentration-Dependent Kinetics of Acetylcholinesterase Inhibition by the Organophosphate Paraoxon","volume":"90","author":"Rosenfeld","year":"2006","journal-title":"Toxicol. Sci."},{"key":"10.1016\/j.jchromb.2021.122943_b0305","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/S0009-2797(99)00039-3","article-title":"Knockout of one acetylcholinesterase allele in the mouse","volume":"119\u2013120","author":"Xie","year":"1999","journal-title":"Chem. Biol. Interact."}],"container-title":["Journal of Chromatography B"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1570023221004244?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1570023221004244?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T23:05:37Z","timestamp":1761606337000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1570023221004244"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10]]},"references-count":61,"alternative-id":["S1570023221004244"],"URL":"https:\/\/doi.org\/10.1016\/j.jchromb.2021.122943","relation":{},"ISSN":["1570-0232"],"issn-type":[{"type":"print","value":"1570-0232"}],"subject":[],"published":{"date-parts":[[2021,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Interspecies comparison of plasma metabolism and sample stabilization for quantitative bioanalyses: Application to (R)-CE3F4 in preclinical development, including metabolite identification by high-resolution mass spectrometry","name":"articletitle","label":"Article Title"},{"value":"Journal of Chromatography B","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jchromb.2021.122943","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"122943"}}